Takayasu  	Takayasu  	 JJ	B-NP
arteritis 	arteritis 	 NN	I-NP
:  	:  	 :	O
epidemiological 	epidemiological 	 CD	B-NP
,  	,  	 ,	O
clinical 	clinical 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
immunogenetic  	immunogenetic  	 JJ	B-NP
features  	features  	 NNS	I-NP
in  	in  	 IN	O
Greece  	Greece  	 NNP	B-NP
Takayasu  	Takayasu  	 NNP	I-NP
arteritis  	arteritis  	 NNS	I-NP
( 	( 	 -LRB-	O
TA 	TA 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
an  	an  	 DT	O
uncommon  	uncommon  	 JJ	O
disease  	disease  	 NN	O
with  	with  	 IN	O
clinical  	clinical  	 JJ	B-NP
heterogeneity  	heterogeneity  	 NN	I-NP
across  	across  	 IN	O
different  	different  	 JJ	O
ethnic  	ethnic  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
aimed  	aimed  	 VBD	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
epidemiological 	epidemiological 	 NN	B-NP
,  	,  	 ,	O
clinical 	clinical 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
immuno-genetic  	immuno-genetic  	 JJ	B-NP
features  	features  	 NNS	I-NP
of  	of  	 IN	I-NP
TA  	TA  	 NNP	I-NP
in  	in  	 IN	O
Greece 	Greece 	 NNP	B-NP
.  	.  	 .	O
Demographic 	Demographic 	 NNP	B-NP
,  	,  	 ,	O
clinical 	clinical 	 JJ	O
,  	,  	 ,	O
laboratory 	laboratory 	 NN	O
,  	,  	 ,	O
angiographic 	angiographic 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
therapeutic  	therapeutic  	 JJ	B-NP
data  	data  	 NNS	I-NP
of  	of  	 IN	O
42  	42  	 CD	O
patients  	patients  	 NNS	O
from  	from  	 IN	O
4  	4  	 CD	O
large  	large  	 JJ	O
referral  	referral  	 NN	B-NP
centers  	centers  	 NNS	I-NP
were  	were  	 VBD	O
retrieved 	retrieved 	 VBN	O
.  	.  	 .	O
Serology  	Serology  	 NNP	B-NP
and  	and  	 CC	O
Human  	Human  	 NNP	B-NP
Lymphocyte  	Lymphocyte  	 NNP	I-NP
Antigen  	Antigen  	 NNP	I-NP
( 	( 	 -LRB-	O
HLA 	HLA 	 NNP	B-NP
)  	)  	 -RRB-	O
typing  	typing  	 NN	O
was  	was  	 VBD	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
22  	22  	 CD	O
patients 	patients 	 NNS	O
.  	.  	 .	O
We  	We  	 PRP	O
studied  	studied  	 VBD	O
37  	37  	 CD	O
women  	women  	 NNS	O
and  	and  	 CC	O
5  	5  	 CD	O
men  	men  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
median  	median  	 JJ	B-NP
age  	age  	 NN	I-NP
of  	of  	 IN	O
31  	31  	 CD	O
years  	years  	 NNS	O
at  	at  	 IN	O
disease  	disease  	 NN	B-NP
onset 	onset 	 NN	I-NP
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
delay  	delay  	 NN	I-NP
in  	in  	 IN	O
diagnosis  	diagnosis  	 NN	O
was  	was  	 VBD	O
24  	24  	 CD	O
months  	months  	 NNS	O
and  	and  	 CC	O
median  	median  	 JJ	B-NP
follow-up  	follow-up  	 NN	I-NP
was  	was  	 VBD	O
47  	47  	 CD	O
months  	months  	 NNS	O
( 	( 	 -LRB-	O
range  	range  	 NN	O
0-178 	0-178 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Constitutional  	Constitutional  	 JJ	O
or  	or  	 CC	O
musculoskeletal  	musculoskeletal  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
were  	were  	 VBD	O
present  	present  	 JJ	O
in  	in  	 IN	O
86 	86 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
especially  	especially  	 RB	O
early  	early  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
disease  	disease  	 NN	B-NP
course 	course 	 NN	I-NP
.  	.  	 .	O
Vascular  	Vascular  	 JJ	B-NP
findings  	findings  	 NNS	I-NP
were  	were  	 VBD	O
universal  	universal  	 JJ	O
with  	with  	 IN	O
reduced  	reduced  	 JJ	O
or  	or  	 CC	O
absent  	absent  	 JJ	O
pulse  	pulse  	 NN	O
being  	being  	 VBG	O
the  	the  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
manifestation  	manifestation  	 NNS	B-NP
( 	( 	 -LRB-	O
98 	98 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Hypertension  	Hypertension  	 NNP	O
was  	was  	 VBD	O
frequent  	frequent  	 JJ	O
( 	( 	 -LRB-	O
78 	78 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Extensive  	Extensive  	 JJ	B-NP
disease  	disease  	 NN	I-NP
prevailed  	prevailed  	 NNS	O
and  	and  	 CC	O
stenotic  	stenotic  	 JJ	B-NP
lesions  	lesions  	 NNS	I-NP
were  	were  	 VBD	O
more  	more  	 RBR	O
common  	common  	 JJ	O
than  	than  	 IN	O
aneurysms  	aneurysms  	 NNS	B-NP
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
40 	40 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Erythrocyte  	Erythrocyte  	 JJ	B-NP
sedimentation  	sedimentation  	 JJ	I-NP
rate  	rate  	 NN	I-NP
and  	and  	 CC	O
C-reactive  	C-reactive  	 JJ	B-NP
protein  	protein  	 NN	I-NP
showed  	showed  	 VBD	O
modest  	modest  	 JJ	O
correlation  	correlation  	 NN	O
with  	with  	 IN	O
disease  	disease  	 NN	B-NP
activity 	activity 	 NN	I-NP
.  	.  	 .	O
HLA-B52  	HLA-B52  	 NNP	B-NP
was  	was  	 VBD	O
expressed  	expressed  	 VBN	O
by  	by  	 IN	O
37 	37 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
vs.  	vs.  	 IN	O
2.4 	2.4 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
controls  	controls  	 NNS	O
( 	( 	 -LRB-	O
p  	p  	 FW	O
< 	< 	 SYM	O
0.001 	0.001 	 FW	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Glucocorticoids  	Glucocorticoids  	 NNP	B-NP
and  	and  	 CC	O
cytotoxic  	cytotoxic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
were  	were  	 VBD	O
used  	used  	 VBN	O
in  	in  	 IN	O
most  	most  	 JJS	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
remission  	remission  	 JJ	B-NP
rates  	rates  	 NNS	I-NP
of  	of  	 IN	O
83 	83 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
42  	42  	 CD	O
surgical  	surgical  	 JJ	B-NP
procedures  	procedures  	 NNS	I-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
with  	with  	 IN	O
success  	success  	 NN	B-NP
rates  	rates  	 NNS	I-NP
of  	of  	 IN	O
87 	87 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
TA  	TA  	 NNP	B-NP
in  	in  	 IN	O
Greece  	Greece  	 NNP	B-NP
clinically  	clinically  	 NN	O
and  	and  	 CC	O
epidemiologically  	epidemiologically  	 NN	O
resembles  	resembles  	 VBZ	O
the  	the  	 DT	O
pattern  	pattern  	 NN	O
of  	of  	 IN	O
disease  	disease  	 NN	O
in  	in  	 IN	O
Japan  	Japan  	 NNP	O
and  	and  	 CC	O
the  	the  	 DT	O
Western  	Western  	 JJ	O
hemisphere 	hemisphere 	 NN	O
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
considerable  	considerable  	 JJ	O
delay  	delay  	 NN	O
in  	in  	 IN	O
diagnosis 	diagnosis 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
may  	may  	 MD	O
partially  	partially  	 RB	O
reflect  	reflect  	 VB	O
failure  	failure  	 NN	O
to  	to  	 TO	O
recognize  	recognize  	 VB	O
a  	a  	 DT	O
rare  	rare  	 JJ	O
disease 	disease 	 NN	O
.  	.  	 .	O
New  	New  	 JJ	B-NP
surrogate  	surrogate  	 JJ	I-NP
markers  	markers  	 NNS	I-NP
are  	are  	 VBP	O
needed  	needed  	 VBN	O
to  	to  	 TO	O
assess  	assess  	 VB	O
disease  	disease  	 NN	B-NP
activity 	activity 	 NN	I-NP
.  	.  	 .	O
Glucocorticoids  	Glucocorticoids  	 NNS	B-NP
are  	are  	 VBP	O
the  	the  	 DT	O
cornerstone  	cornerstone  	 NN	O
of  	of  	 IN	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
cytotoxic  	cytotoxic  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
are  	are  	 VBP	O
frequently  	frequently  	 RB	O
used  	used  	 VBN	O
as  	as  	 IN	O
steroid  	steroid  	 JJ	B-NP
sparing  	sparing  	 JJ	O
agents 	agents 	 NNS	O
.  	.  	 .	O
